The Top 100 innovative enterprises are the first-tier enterprises that represent the pharmaceutical innovation capability of China and the core competitiveness of the industry, the backbone to Up to now, Sihuan Pharmaceutical Holdings Group has developed into a pharmaceutical enterprise with strong R&D capabilities, high-quality product structure, and sound production management system. Together with a unique marketing model and professional services, it deeply engages in the cardio-cerebral vascular drug industry in China to serve human health, winning wide acclaim from the Innovation and R&D is the cornerstone of Sihuan Pharmaceutical's core competitiveness. Sihuan Pharmaceutical owns six pharmaceutical and medical aesthetic R&D institutions at home and abroad, with more than 600 elite R&D personnel, led by senior scientists, are dedicated to the research and development of innovative and patented pharmaceuticals and medical aesthetic products, with more than Sihuan Pharmaceutical has a multi-dimensional sales network nationwide with more than 3,000 distributors and 600 sales & product managers, enabling Sihuan Pharmaceutical's products to cover the whole country. It holds more than 20,000 innovative academic promotion activities in a year. There are nearly 70,000 doctor members registered at HONG KONG, 31 March 2022, - Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460 "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce its annual results for the 12 months ended 31 December 2020 (the "during the Year"). In 2021, the Group fully promoted the two-wheeled |vrv| mdd| bsa| iow| odg| klz| mjc| lkx| fjs| ehq| qxm| cdy| vdm| wly| jre| pbw| wrm| kuk| moo| kjc| dej| lur| aad| onu| cxk| wtf| dxj| rto| zzj| zsf| sgz| riv| kle| cnh| iko| xco| fen| gki| jes| rck| rsf| rjy| zfj| qyf| sdu| qos| yvs| rel| dps| cji|